Related references
Note: Only part of the references are listed.The SIDER database of drugs and side effects
Michael Kuhn et al.
NUCLEIC ACIDS RESEARCH (2016)
Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress
Hesham M. Korashy et al.
TOXICOLOGY LETTERS (2016)
DSigDB: drug signatures database for gene set analysis
Minjae Yoo et al.
BIOINFORMATICS (2015)
Detection of Binding Site Molecular Interaction Field Similarities
Matthieu Chartier et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2015)
PockDrug-Server: a new web server for predicting pocket druggability on holo and apo proteins
Hiba Abi Hussein et al.
NUCLEIC ACIDS RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
sc-PDB: a 3D-database of ligandable binding sites-10 years on
Jeremy Desaphy et al.
NUCLEIC ACIDS RESEARCH (2015)
The ChEMBL bioactivity database: an update
A. Patricia Bento et al.
NUCLEIC ACIDS RESEARCH (2014)
Differential Transcriptional Effects of EGFR Inhibitors
Miroslav Blumenberg
PLOS ONE (2014)
Successful EGFR-TKI Rechallenge of Leptomeningeal Carcinomatosis after Gefitinib-induced Interstitial Lung Disease
Shinji Nakamichi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Identification of Similar Binding Sites to Detect Distant Polypharmacology
Xavier Jalencas et al.
MOLECULAR INFORMATICS (2013)
Novel Computational Approaches to Polypharmacology as a Means to Define Responses to Individual Drugs
Lei Xie et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Theonie Anastassiadis et al.
NATURE BIOTECHNOLOGY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
Marcello Tiseo
Drug Design Development and Therapy (2010)
Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model
Roger L. Chang et al.
PLOS COMPUTATIONAL BIOLOGY (2010)
Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib
Germano Zampa et al.
LUNG CANCER (2008)
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Beth Apsel et al.
NATURE CHEMICAL BIOLOGY (2008)
The role of the EGFR signaling in tumor microenvironment
Antonella De Luca et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Analysis of drug-induced effect patterns to link structure and side effects of medicines
AF Fliri et al.
NATURE CHEMICAL BIOLOGY (2005)
In vitro safety pharmacology profiling:: an essential tool for successful drug development
S Whitebread et al.
DRUG DISCOVERY TODAY (2005)
Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis
N Normanno et al.
ENDOCRINE-RELATED CANCER (2005)
The many roles of computation in drug discovery
WL Jorgensen
SCIENCE (2004)
United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets
MH Cohen et al.
CLINICAL CANCER RESEARCH (2004)
AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity
P Traxler et al.
CANCER RESEARCH (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
